Nuvation Drug Patent Portfolio
Nuvation owns 1 orange book drug protected by 2 US patents Given below is the list of Nuvation's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9187489 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | 03 Jun, 2033 | Active |
| US9751887 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | 03 Jun, 2033 | Active |
Latest Legal Activities on Nuvation's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Nuvation.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 02 Dec, 2025 | US9187489 |
| transaction for FDA Determination of Regulatory Review Period | 02 Dec, 2025 | US9751887 |
| Second letter to regulating agency to determine regulatory review period | 27 Oct, 2025 | US9187489 |
| Second letter to regulating agency to determine regulatory review period | 27 Oct, 2025 | US9751887 |
| Information Disclosure Statement (IDS) Filed | 15 Oct, 2025 | US9187489 |
| Letter from FDA or Dept of Agriculture re PTE application | 15 Oct, 2025 | US9187489 |
| Letter from FDA or Dept of Agriculture re PTE application | 15 Oct, 2025 | US9751887 |
| Information Disclosure Statement (IDS) Filed | 15 Oct, 2025 | US9751887 |
| Initial letter Re: PTE Application to regulating agency | 05 Aug, 2025 | US9751887 |
| Initial letter Re: PTE Application to regulating agency | 05 Aug, 2025 | US9187489 |
| Patent Term Extension Application under 35 USC 156 Filed | 01 Aug, 2025 | US9187489 |
| Patent Term Extension Application under 35 USC 156 Filed | 01 Aug, 2025 | US9751887 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Mar, 2025 | US9751887 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 May, 2023 | US9187489 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Mar, 2021 | US9751887 |
Nuvation's Family Patents
Clinical Trials
Recent Clinical Trials by Nuvation:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease | Nuvation Bio Inc. | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Nuvation Bio Inc. | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib | Nuvation Bio Inc. | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE1 |
| A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients | Nuvation Bio Inc. | NA |
RECRUITING
(Apr 1, 2026)
| PHASE3 |
Nuvation Drug List
Given below is the complete list of Nuvation's drugs and the patents protecting them.
1. Ibtrozi
Ibtrozi is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9187489 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors |
03 Jun, 2033
(6 years from now)
| Active |
| US9751887 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors |
03 Jun, 2033
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ibtrozi's drug page